VBI Vaccines Inc. (VBIV)
After hours:
| Previous close | 0.5802 |
| Open | 0.5900 |
| Bid | 0.5659 x 100 |
| Ask | 0.6240 x 100 |
| Day's range | 0.5899 - 0.6069 |
| 52-week range | 0.4500 - 3.4700 |
| Volume | |
| Avg. volume | 428,887 |
| Market cap | 17.066M |
| Beta (5Y monthly) | 1.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.5400 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
Business WireVBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
CAMBRIDGE, Mass., May 29, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients. These data will be presented in a poster session at the 2024 American Society of Clinical Oncology
Business WireVBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
CAMBRIDGE, Mass., May 22, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Me
Business WireVBI Vaccines Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 15, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2024.
